



**70 years of trust, performance and
lasting partnerships**

Key results recorded in the Quarter I 2026

162
Million lei

Total revenue of 162 million lei

14.7%

Gross profit cumulated with the value of the claw-back tax consolidated a business return of 14,7%

\$

Consolidation of exports in foreign currency compared to last year

Loc 4

Consolidated in terms of the consumption of boxes on the Romanian generic and over-the-counter market, with a market share of 5.5%

Ranked 1st

Maintains the leading position in terms of value in the hospital segment for prescription and non-prescription generics, with a 12.8% market share.

2,1484
lei

Average value of share: 2.1484 lei/share.



+1%


Consolidated the net book asset at the value of 944.6 million lei, which represents a 1% increase compared to 2025

STEP

Contracting of promotion services and project management consultancy

Antibiotice S.A. - a performance-oriented company

-  **ATB symbol**
-  **Listing date: April 16, 1997**
-  **Market capitalization of 1.22 billion lei***
-  **Number of shares: 671.338.040**
-  **Nominal share value: 0.10 lei/share**
-  **Share capital: 67 million lei**
-  **Minimum price: 1.7520 lei/share**
-  **Maximum price: 2.5500 lei/share**



* Information valid as of March 31, 2026


Antibiotice - o companie pentru care merită să lucrezi

Highly-educated specialists (52.91% - 718)

Secondary education employees (47.09% - 639)


1357 EMPLOYEES

*Highly educated specialists
Top specializations*



- Chemical engineer 20,33%
- Economist 21,17%
- Chemist, physicist, biologist 17,27%
- Engineer – other specializations 14,90%
- Pharmacist, physician, medical bioengineer 16,71%
- Other professions 9,61%

*Secondary education employees
Top professions*



- Pharmaceutical products site operator 41,21%
- Active substances site operator 16,85%
- Operation, maintenance, production equipment operator, machinist, automatist, mechanic, technician 18, 32%
- Quality control laboratory assistant 6,41%
- Logistics operator 6,41%

→ The employee retention rate as of 31.03.2026 is 98.82%

→ 11,32 hours – The average number of training hours/employee as of 31.03.2026

Antibiotice - a knowledge and performance-driven company

ACADEMIA A+ - a knowledge management platform (staff recruitment and business skills development)

TECHNICAL COLLEGE
a+



BUSINESS SCHOOL a+



PRE-UNIVERSITY & UNIVERSITY ENVIRONMENT

- ❑ Internships for 178 pupils from the technical and dual education system and for 78 students
- ❑ Educational visits within the “A Different Schooling Week” program 415 pupils and 15 students
- ❑ Partner of the Center of Excellence for students of the Faculty of Economics and Business Administration
- ❑ The project “Education in Action” project: Improving the Accessibility and Relevance of Vocational and Technical Education through Internships within Antibiotice S.A.”. In the reporting period, 72 pupils completed their internships.
- ❑ The “AntibioticeSkills project: Improving students and their adaptation to the labor market.” In the reporting period, internships for 66 students were conducted.

BUSINESS SKILLS DEVELOPMENT

- ❑ In the first quarter of 2026, 15,400 hours of classes were held, with over 1,400 employees involved.
- ❑ The mentoring program launched in 2022 - until present 44 employees have been trained and received trainer certification, 30 employees are recognized with mentor certification, 115 colleagues attended the course and hold a public speaking certificate.
- ❑ The e-learning platform has been accumulating 630 users since its launch, about 8,600 hours completed by participants, 1,200 certifications awarded in areas such as marketing and communication, personal development, compliance, health and safety, team management, MS Office and customer service.
- ❑ Bookster, a program launched in 2020 that gives employees the opportunity to borrow books: 320 active users and over 20,115 borrowed books.

Antibiotice

In the service of life for a lifetime

12 therapeutic classes – 199 products
 > 500 marketing authorizations in over 50 countries
38 critical molecules
56 critical products

Oral Solid Products Division

99 products for human use:

- **Rx medicinal products** from the following therapeutic classes:
 - anti-infective products for systemic use (penicillins, cephalosporins, fluoroquinolones, macrolides, tetracyclines, antituberculosis, antivirals)
 - Cardiovascular system
 - Digestive tract and metabolism
 - Central nervous system
- **OTC products** complementary to the prescription medication

Topical Products Division

56 products for human use:

- **products intended for:**
 - Dermatological conditions
 - Musculo-skeletal conditions
 - Genital-urinary conditions
 - Hemorrhoidal conditions
 - Ophthalmological conditions

Sterile Products Division

40 products for human use:

- prescription products from the therapeutic class of anti-infectives for systemic use (from the class of β -lactam penicillins, cephalosporins, carbapenems, polymyxin, tetracycline, glycopeptides);
- OTC (Over the Counter) products.

Active Substances Division

The **Nystatin** range of active substances is obtained through the biosynthesis process, by cultivating the microorganism ***Streptomyces noursei*** on nutrient media, followed by the isolation and purification processes of the active substance..

Antibiotice – a company operating at international standards



EU GMP

8 manufacturing flows



US FDA

Sterile injectable powders and Nystatin, active substance



COS (Certificate of Suitability) issued by EDQM

Standard and micronized Nystatin



Management System
ISO 9001:2015
ISO 14001:2015
ISO 45001:2018

www.tuv.com
ID 9000004194

ISO TÜV RHEINLAND certification for integrated management

Quality, environment, occupational health and safety ISO 9001, ISO 14001, ISO 45001




EcoVadis – Global Sustainability Assessment Platform

S-a obținut medalia Silver – Our company was granted the Silver medal which places it in "Advanced" category and in the top 15% of companies analyzed globally in the pharmaceutical industry.


Antibiotice on the pharmaceutical market in România

In Quarter I 2026 on the domestic market, Antibiotice S.A.:



Antibiotice - an international brand

Present in over 50 countries worldwide



Commercial representations (marketing and sales)


- North America (U.S., Canada)
- South America (Brasil, Mexico, Columbia)
- Europe (UK, Germany, Italy, the Northern Countries)
- India
- China
- Australia

World leader in the production of active substance Nystatin, an antifungal antibiotic

Business representatives:

- Republic of Moldova
- Serbia
- Vietnam
- Saudi Arabia

Antibiotice - an internationally recognized Romanian brand



The comprehensive income

Indicators	March 31, 2026	March 31, 2025	March 31, 2026/ March 31, 2025
A. Total revenues, of which:	162,270,055	180,032,464	-9.90%
1. Operational values	158,414,318	175,754,412	-9.90%
1.1 Revenue from contracts with customers (turnover), of which:	136,533,313	161,117,259	-15.30%
Revenue from the sale of products made on the company's own sites	111,544,761	128,664,758	-13.30%
Revenue from the sale of products on partner sites	24,564,440	31,699,084	-22.50%
Revenue from the provision of services	424,112	753,417	-43.70%
1.2 Other operating income	2,147,464	212,142	912.30%
1.3 Revenue from subsidies	125,039	100,653	24.20%
1.4 Revenue related to product inventory costs	15,573,008	11,768,780	32.30%
1.5 Revenue from research and development projects	4,035,494	2,555,578	57.90%
2. Financial income	3,855,736	4,278,052	-9.90%
Income from exchange rate differences	3,855,728	4,277,788	-9.90%
Bank interest income:	8	264	-96.80%
B. Total expenses, of which:	149,705,831	144,688,755	3.50%
1. Operational expenses:	144,660,191	139,462,192	3.70%
Expenses on raw materials and consumables:	45,653,170	40,918,794	11.60%
Expenses on products made on partner sites	17,358,006	18,599,300	-6.70%
Electricity expenses	3,114,229	2,806,538	11.00%
Natural gas expenses	3,328,286	3,757,245	-11.40%
Expenses for drinking water and sewage	786,575	635,269	23.80%
Personnel expenses	37,604,889	39,369,450	-4.50%
Other operating expenses (*)	22,490,570	20,553,160	9.40%
Depreciation and impairment of fixed assets, net	14,324,467	12,822,436	11.70%
2. Financial expenses	5,045,639	5,226,563	-3.50%
Expenses form exchange rate differences	3,947,321	4,270,711	-7.60%
Bank interest expenses	1,098,318	955,852	14.90%
Operational result	13,754,127	36,292,220	-62.10%
Financial result	-1,189,903	-948,511	-25.40%
Gross profit	12,564,224	35,343,709	-64.50%
Income tax expenses	711	2,701,462	-99.97%
Net profit	12,563,513	32,642,247	-61.50%
Earnings per share (EPS)	0.0187	0.0486	-61.50%

Financial balance

Indicators	March 31, 2026	December 31, 2025	March 31, 2026/ December 31, 2025
Current liquidity (Current assets-Cash-Current income tax receivable) / Short term bank debts (>1.2)	3.75	5.03	-25%
Total bank debts/EBITDA (<3.5)	3.02	1.88	60%
Total bank debts/Equity (<1)	0.33	0.25	31%

Implementation of the investment plan for Quarter I2026

**Total investments:
10.25 million lei**

- developing the product portfolio through in-house research:
4.19 million lei
- Investments in new production sites:
2.35 million lei
- Digitalization strategy: **1.93 million lei**

**Investments for strategic development
8.47 million lei**



- adapting to the development trends of the industrial platform, utility supply and distribution infrastructure, storage of raw materials and finished products, transportation and connection to the national road system: **1.14 million lei**
- investments in the Integrated Management System (Quality, Environment, Sustainability, Occupational Health and Safety):
0.33 million lei
- investments in modernizing the existing sites and equipmen: **0.31 million lei**

Investments for business strengthening 1.78 million lei



Antibiotice

Știință și suflet



www.antibiotice.ro

